

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 <u>Company</u> Eli Lilly (pirtobrutinib) <u>Patient/carer groups</u> African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer 52 Cancer Black Care Chronic Lymphocytic Leukaemia Support Association Follicular Lymphoma Foundation Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Kararwa Leukaemia Trust Leukaemia Care Leukaemia Care Leukaemia UK Lymphoma Action Macmillan Cancer Support Maggie's Centres Marie Curie 	 <u>General</u> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health – Northern Ireland Healthcare Improvement Scotland Hospital Information Services – Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Blood and Transplant NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care WMUK <u>Healthcare Professional groups</u> Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Blood Transfusion Society British Geriatrics Society 	 <u>Possible comparator companies</u> Abbvie (venetoclax) AstraZeneca (acalabrutinib) BeiGene UK (zanubrutinib) Celltrion Healthcare (rituximab) Gilead Sciences (idelalisib) Janssen-Cilag (ibrutinib) Pfizer (rituximab) Roche (rituximab) Sandoz (rituximab) <u>Relevant research groups</u>

Provisional stakeholder list for the evaluation of pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269] Issue date: February 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Haematology British Society of Blood and Marrow Transplantation and Cellular Therapy British Society of Interventional Radiology British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Radiologists Royal College of Radiologists Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Cutaneous Lymphoma Group UK Oncology Nursing Society 	 Cochrane Haematology Cochrane UK Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269] Issue date: February 2025 © National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.